Journal Home
Search for

Volume 104, Issue 2, Pages 118-124 (February 2010)


View previous. 8 of 20 View next.

Psychometric validation of the Rhinitis Control Assessment Test: a brief patient-completed instrument for evaluating rhinitis symptom control

Michael Schatz, MD, Eli O. Meltzer, MD, Robert Nathan, MD, M. Jennifer Derebery, MD§, Matthew Mintz, MD, Richard H. Stanford, PharmDCorresponding Author Informationemail address, Anand A. Dalal, PhD, Mary Jane Silvey, MBA, Mark Kosinski, MA#

Received 28 July 2009; received in revised form 30 October 2009; accepted 30 November 2009.

Background

Allergic rhinitis is common, but a validated tool for comprehensive assessment of disease control is not available.

Objective

To develop a simple patient-completed instrument (the Rhinitis Control Assessment Test [RCAT]) to help detect problems with control of rhinitis symptoms.

Methods

During a visit to an allergy specialist, 410 patients with allergic rhinitis completed a Total Nasal Symptom Score (TNSS) assessment and the 26-item developmental RCAT. Physicians also completed a global assessment of rhinitis symptom control for each patient.

Results

Stepwise regression methods identified 6 items from the developmental RCAT (frequency of nasal congestion, sneezing, and watery eyes; sleep interference; activity avoidance; and self-assessed control) that were most predictive of the allergist's global rating of rhinitis symptom control. A summated rating scale from these 6 items showed good convergent validity (r > 0.70) with scale scores from the TNSS. The discriminant validity of the 6-item scale was demonstrated as mean RCAT scale scores differed significantly across groups of patients differing in physician-rated disease severity (F = 54.4), TNSS severity (F = 193.8), and physician-recommended change in therapy (F = 50.6) (P < .001 for all).

Conclusions

The RCAT, a 6-item patient-completed instrument, has satisfactory psychometric properties and seems to be a valid tool for assessing control of allergic rhinitis. Further validation studies will provide confirmation.

 Kaiser Permanente, San Diego, California

 Allergy and Asthma Medical Group and Research Center, San Diego, California

 Asthma and Allergy Associates, Colorado Springs, Colorado

§ House Ear Clinic, Los Angeles, California

 George Washington University School of Medicine, Washington, DC

 GlaxoSmithKline, Research Triangle Park, North Carolina

# QualityMetric, Lincoln, Rhode Island

Corresponding Author InformationRequests for reprints should be addressed to: Richard H. Stanford, PharmD, GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709

 Disclosures: Drs Stanford and Dalal and Ms Silvey are employees of GlaxoSmithKline.

 Funding Sources: GlaxoSmithKline funded this research.

PII: S1081-1206(09)00066-0

doi:10.1016/j.anai.2009.11.063


View previous. 8 of 20 View next.